---
title: Management of Immune Thrombotic Thrombocytopenic Purpura without Therapeutic
  Plasma Exchange
date: '2024-06-05'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38838300/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240606180757&v=2.18.0.post9+e462414
source: Blood
description: Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening
  autoimmune disorder caused by ADAMTS13 deficiency. Caplacizumab, an anti-VWF nanobody,
  is approved for iTTP treatment, reducing the need for therapeutic plasma exchange
  (TPE) and improving platelet count recovery and survival. We conducted a retrospective
  study on 42 acute iTTP cases in Austria and Germany, treated with a modified regimen
  aimed at avoiding TPE if platelet count increased after the first ...
disable_comments: true
---
Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening autoimmune disorder caused by ADAMTS13 deficiency. Caplacizumab, an anti-VWF nanobody, is approved for iTTP treatment, reducing the need for therapeutic plasma exchange (TPE) and improving platelet count recovery and survival. We conducted a retrospective study on 42 acute iTTP cases in Austria and Germany, treated with a modified regimen aimed at avoiding TPE if platelet count increased after the first ...